VYNE Therapeutics (VYNE) Form 3 Menlo Therapeutics / David J Collier ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Presidio Partners 2007 GP, L.P.

(Last) (First) (Middle)

655 MONTGOMERY STREET, SUITE 6-161

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/24/2018

3. Issuer Name and Ticker or Trading Symbol
Menlo Therapeutics, Inc. [ MNLO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,415,421	I	By Presidio Partners 2007, L.P.(1)
Common Stock	36,292	I	By Presidio Partners 2007 (Parallel), L.P.(2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock	(3)	(3)	Common Stock	2,584	(3)	I	By Presidio Partners 2007, L.P.(1)
Series A Preferred Stock	(3)	(3)	Common Stock	66	(3)	I	By Presidio Partners 2007 (Parallel), L.P.(2)
Series B Preferred Stock	(4)	(4)	Common Stock	849,794	0.00(4)	I	By Presidio Partners 2007, L.P.(1)
Series B Preferred Stock	(4)	(4)	Common Stock	21,789	0.00(4)	I	By Presidio Partners 2007 (Parallel), L.P.(2)
Series C Preferred Stock	(5)	(5)	Common Stock	127,269	0.00(5)	I	By Presidio Partners 2007, L.P.(1)
Series C Preferred Stock	(5)	(5)	Common Stock	3,263	0.00(5)	I	By Presidio Partners 2007 (Parallel), L.P.(2)

1. Name and Address of Reporting Person^*

Presidio Partners 2007 GP, L.P.

(Last) (First) (Middle)

655 MONTGOMERY STREET, SUITE 6-161

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Presidio Partners 2007, L.P.

(Last) (First) (Middle)

C/O PRESIDIO PARTNERS 2007 GP, L.P.

655 MONTGOMERY STREET, SUITE 6-161

(Street)

SAN FRANCISCO CA

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Presidio Partners 2007 (Parallel), L.P.

(Last) (First) (Middle)

C/O PRESIDIO PARTNERS 2007 GP, L.P.

655 MONTGOMERY STREET, SUITE 6-161

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Collier David J

(Last) (First) (Middle)

C/O PRESIDIO PARTNERS 2007 GP, L.P.

655 MONTGOMERY STREET, SUITE 6-161

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Watson James F

(Last) (First) (Middle)

C/O PRESIDIO PARTNERS 2007 GP, L.P.

655 MONTGOMERY STREET, SUITE 6-161

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Sohail Faysal A.

(Last) (First) (Middle)

C/O PRESIDIO PARTNERS 2007 GP, L.P.

655 MONTGOMERY STREET, SUITE 6-161

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Explanation of Responses:

1. Securities directly held by Presidio Partners 2007, L.P. ("Presidio Partners"). Presidio Partners 2007 GP, L.P. ("Presidio GP") is the sole general partner of Presidio Partners. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio GP, and may be deemed to have voting control and investment power over the securities held by Presidio Partners, but disclaim beneficial ownership of the securities held by Presidio Partners, except to the extent of their pecuniary interest therein.

2. Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio GP, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein.

3. Each of the 6,971 and 179 shares of Series A Stock held by Presidio Partners and Presidio Parallel, respectively, is convertible, at any time, at the holder's election, into 0.3707 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock will automatically convert into 0.3707 shares of the Issuer's common stock. The Series B Preferred Stock has no expiration date.

4. Each of the 2,292,320 and 58,777 shares of Series B Stock held by Presidio Partners and Presidio Parallel, respectively, is convertible, at any time, at the holder's election, into 0.3707 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock will automatically convert into 0.3707 shares of the Issuer's common stock. The Series B Preferred Stock has no expiration date.

5. Each of the 343,310 and 8,803 shares of Series C Preferred Stock held by Presidio Partners and Presidio Parallel, respectively, is convertible, at any time, at the holder's election, into 0.3707 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series C Preferred Stock will automatically convert into 0.3707 shares of the Issuer's common stock. The Series C Preferred Stock has no expiration date.

Remarks:

	Presidio Partners 2007 GP, L.P. By: Presidio Partners 2007 GP LLC, its General Partner, /s/ David J. Collier, Manager	01/24/2018
	PRESIDIO PARTNERS 2007, L.P. By: Presidio Partners 2007 GP, L.P, its General Partner By: Presidio Partners 2007 GP LLC, its General Partner, /s/ David J. Collier, Manager	01/24/2018
	PRESIDIO PARTNERS 2007 (Parallel), L.P. By: Presidio Partners 2007 GP, L.P, its General Partner By: Presidio Partners 2007 GP LLC, its General Partner, /s/ David J. Collier, Manager	01/24/2018
	/s/ David J. Collier, Manager	01/24/2018
	/s/ James F. Watson, Manager	01/24/2018
	/s/ Faysal A. Sohail, Manager	01/24/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.